[Controversy about using calcium antagonists for treatment of coronary disease and hypertension].
Calcium antagonists are widely used in therapy of hypertension and angina pectoris. Their advantage is good efficacy, relatively few and not dangerous side effects and first of all lack of bad metabolic effects (hypokalemia, hyperuricemia, hyperinsulinemia and hyperlipoproteinemia). In contrast to beta-blockers and diuretics, which decline mortality from myocardial infarctions and strokes there are not similar information concerning calcium antagonists. Two meta-analysis from 1995 unexpectedly suggest, that some preparations of calcium antagonists increase mortality from myocardial infarctions and strokes. In our paper we discuss possible pathogenetic (harmful) mechanisms, pay attention to each class of calcium antagonists and time of action of the particular drugs. Short acting nifedipine formulation should be withdrawn from chronic hypertension and angina pectoris therapy. Ongoing multicenter trials in several European countries and in USA will decide the usefulness of other calcium antagonists preparations.
Głuszek
J
J
Kliniki Nadciśnienia Tetniczego Instytutu Kardiologii Akademii Medycznej w Poznaniu.
Pawlaczyk-Gabriel
K
K
D002121:Calcium Channel Blockers / Q000009:adverse effects*; D002561:Cerebrovascular Disorders / Q000401:mortality; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000401:mortality; D009543:Nifedipine / Q000009:adverse effects
D002121:Calcium Channel Blockers; D009543:Nifedipine
Kontrowersje wokół stosowania antagonistów wapnia w niewydolności wieńcowej i nadciśnieniu tetniczym.